QUALCOMM Incorporated – Consensus Indicates Potential 44.9% Upside

DirectorsTalk Interviews

QUALCOMM Incorporated with ticker code (QCOM) have now 32 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 289.38 and 130 with a mean TP of 186.64. Given that the stocks previous close was at 128.85 this is indicating there is a potential upside of 44.9%. The 50 day moving average now sits at 141.55 while the 200 day moving average is 153.3. The market capitalisation for the company is $144,699m. You can visit the company’s website by visiting: https://www.qualcomm.com

The potential market cap would be $209,597m based on the market concensus.

QUALCOMM Incorporated engages in the development and commercialization of foundational technologies for the wireless industry worldwide. The company operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on 3G/4G/5G and other technologies for use in wireless voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of wireless products comprising products implementing CDMA2000, WCDMA,LTE and/or OFDMA-based 5G standards and their derivatives. The QSI segment invests in early-stage companies in various industries, including 5G, artificial intelligence, automotive, consumer, enterprise, cloud, and IoT, and investment for supporting the design and introduction of new products and services for voice and data communications, new industries, and applications. It also provides development, and other services and related products to the United States government agencies and their contractors. QUALCOMM Incorporated was incorpotared in 1985 and is headquartered in San Diego, California.

Share on:
Find more news, interviews, share price & company profile here for:

    Likewise granted approval for 20,000 sq ft expansion of Newport facility

    Likewise Group has received planning permission to extend its Newport warehouse by 20,000 sq ft, creating a 55,000 sq ft distribution hub. The development will be funded through internal cash flow.

    Cerillion secures £17.3m follow-on contracts with major European customer

    Cerillion has signed two agreements worth a combined £17.3 million with an existing European customer, following an £8 million services contract announced in May 2025.

    Avation reports US$110m revenue and strengthened balance sheet for FY25

    Avation expects revenue of around US$110 million for the year to 30 June 2025. The company has reduced outstanding bond debt to US$298 million through repurchases and improved its credit ratings with Moody’s and Fitch.

    JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

    JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

    Golden Matrix reports record August revenue of $17.8m, up 18% year-on-year

    Golden Matrix posted record August revenues of $17.8m, up 18% from last year, with July revenues also rising 24% to $15.7m. Strong performance came from Meridianbet’s sports betting and RKings’ tournaments, positioning the group for record Q3 results.

    HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

    HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

      Search

      Search